GovBidPulseFormDPulseAccessPulseCitePulseLocalSchemaPulseIntelligence feedsSupport

ClinicalTrialStartPulse: this week's new records

ClinicalTrialStartPulse added 25 new public records since 2026-10-28; the newest is dated 2026-11-03. The list updates automatically from the source data, and each item links to its full record and the official source. A free weekly email version is available with confirmed opt-in.

25 new public records since 2026-10-28, newest first. Updated automatically from the ClinicalTrialStartPulse source data.

  1. Genmab: Phase 3 study started recruiting, 600 planned (Colorectal Cancer) 2026-11-03
  2. GlaxoSmithKline: Phase 3 study started recruiting, 610 planned (Neoplasms, Endometrial) 2026-11-03
  3. Merck Sharp & Dohme LLC: Phase 3 study started recruiting, 1104 planned (Diabetic Retinopathy, Macular Edema) 2026-11-03
  4. NervGen Pharma: Phase 3 study started recruiting, 150 planned (Chronic Spinal Cord Injury) 2026-11-03
  5. Nurix Therapeutics, Inc.: Phase 2 study started recruiting, 150 planned (B-cell Lymphoma, Chronic Lymphocytic Leukemia) 2026-11-03
  6. Janssen Research & Development, LLC: Phase 2 study closed enrollment, 333 enrolled (Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma) 2026-11-03
  7. Janssen Research & Development, LLC: Phase 2 study closed enrollment, 166 enrolled (Lymphoma, Non-Hodgkin, Lymphoma, B-Cell) 2026-11-03
  8. Janssen Research & Development, LLC: Phase 2 study closed enrollment, 305 enrolled (Carcinoma, Non-Small-Cell Lung) 2026-11-03
  9. Janssen Research & Development, LLC: Phase 3 study closed enrollment, 743 enrolled (Multiple Myeloma) 2026-11-03
  10. Janssen-Cilag Ltd.: Phase 3 study closed enrollment, 120 enrolled (Crohn's Disease) 2026-11-03
  11. Genmab: Phase 3 study closed enrollment, 191 enrolled (PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC) 2026-11-03
  12. Janssen-Cilag Ltd.: Phase 3 study closed enrollment, 288 enrolled (Fistulizing Crohns Disease, Perianal Crohns Disease) 2026-11-03
  13. Janssen Research & Development, LLC: Phase 2 study closed enrollment, 168 enrolled (Multiple Myeloma) 2026-11-03
  14. Janssen Research & Development, LLC: Phase 3 study closed enrollment, 539 enrolled (Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma) 2026-11-03
  15. Janssen Research & Development, LLC: Phase 3 study closed enrollment, 159 enrolled (Crohn Disease, Colitis, Ulcerative) 2026-11-03
  16. AstraZeneca: Phase 3 study closed enrollment, 181 enrolled (Chronic Rhinosinusitis With Nasal Polyps) 2026-11-03
  17. Janssen Research & Development, LLC: Phase 3 study closed enrollment, 864 enrolled (Multiple Myeloma) 2026-11-03
  18. Teva Branded Pharmaceutical Products R&D LLC: Phase 2 study closed enrollment, 349 enrolled (Multiple System Atrophy) 2026-11-03
  19. Genmab: Phase 2 study closed enrollment, 543 enrolled (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma) 2026-11-03
  20. Janssen Pharmaceutica N.V., Belgium: Phase 3 study closed enrollment, 691 enrolled (Prostatic Neoplasms) 2026-11-03
  21. Janssen Research & Development, LLC: Phase 2 study closed enrollment, 208 enrolled (Multiple Myeloma) 2026-11-03
  22. Janssen Research & Development, LLC: Phase 2 study closed enrollment, 235 enrolled (Non-Muscle Invasive Bladder Neoplasms) 2026-11-03
  23. Janssen Research & Development, LLC: Phase 3 study closed enrollment, 112 enrolled (Colitis, Ulcerative) 2026-11-03
  24. Apogee Therapeutics, Inc.: Phase 2 study closed enrollment, 470 enrolled (Atopic Dermatitis) 2026-11-03
  25. Janssen Research & Development, LLC: Phase 2 study closed enrollment, 189 enrolled (Dermatitis, Atopic) 2026-11-03

Get this digest by email (free)

We will email you one confirmation link now. The weekly digest starts only after you confirm, and every email has a one-click unsubscribe.

Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.

Search and filter all records RSS

Often used together